Tukysa Combo Approved for RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer

Summary: Good news for people fighting a tough type of advanced colon cancer! The FDA just fast-tracked a new treatment called the Tukysa combo. It is designed for adults with "HER2-positive" colorectal cancer that has spread and stopped responding to regular chemotherapy.

Here is the best part: this new treatment doesn't use standard chemotherapy. Instead, it combines a daily pill (Tukysa) with an IV medicine (trastuzumab) to specifically target the cancer cells. In a study called the MOUNTAINEER trial, 38% of patients saw their tumors shrink, and the positive results lasted for about a year on average.

While there are some side effects like diarrhea, tiredness, and rashes, doctors are thrilled to offer a "chemo-free" option. This gives patients a much better chance at living their normal lives without the harsh effects of traditional chemo.

For more details, see oncologynurseadvisor at oncologynurseadvisor.com/home/cancer-types/colorectal-cancer/tukysa-combo-approved-for-ras-wild-type-her2-positive-metastatic-colorectal-cancer/ (opens in new tab)